• STAAR Surgical, which designs and manufactures implantable lenses for refractive eye surgery, is heading into its 2026 first‑quarter earnings report on 13 May amid expectations for a very large year-on-year revenue increase and a move from loss to profit after prior financial pressure.
• This anticipated turnaround follows two years of revenue declines, weaker free cash flow and reduced returns on invested capital, putting management’s guidance and the durability of any profitability improvement under particularly close investor scrutiny.
• We’ll now examine how expectations for a shift back to profitability could reshape STAAR Surgical’s existing investment narrative and risk balance.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.

STAAR Surgical Investment Narrative Recap

To hold STAAR Surgical, you need to believe its implantable lenses can earn durable, profitable growth despite recent losses and volatility in key markets like China. The latest earnings expectations, pointing to a sharp revenue rebound and a swing to profit, sharpen the near term catalyst around proof of sustainable margin improvement, while the biggest risk remains whether this recovery is real demand or just a temporary snapback after two years of financial strain.

The most relevant recent development is the FDA’s expanded age indication for EVO and EVO+ lenses in the United States, which broadens the potential pool of eligible patients. In the context of the coming earnings release, this regulatory win gives investors a concrete product based reason to watch for any early signs of stronger procedure volumes or improved pricing power, both of which could help support the profitability story that current expectations are building in.

Yet behind the optimism around a return to profit, investors should be aware of the ongoing uncertainty tied to China distributor inventory and weak consumer demand...

STAAR Surgical's narrative projects $363.2 million revenue and $24.6 million earnings by 2029. This requires 14.9% yearly revenue growth and a $105.0 million earnings increase from -$80.4 million today.

Uncover how STAAR Surgical's forecasts yield a $21.11 fair value, a 23% downside to its current price.

Exploring Other Perspectives

Before this earnings update, the most optimistic analysts were assuming revenue could reach about US$390,000,000 by 2029, yet that view sits in sharp contrast to concerns about STAAR’s heavy reliance on a single lens platform and how competitive or regulatory setbacks could quickly change the story.

Explore 2 other fair value estimates on STAAR Surgical - why the stock might be worth 23% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your STAAR Surgical research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free STAAR Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STAAR Surgical's overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.